Skip to content
Pass Duke Elder
Textbook / Chapter 13 / Ocular pharmacology and therapeutics

How drugs reach the eye

The eye is built to keep foreign substances out, so getting a drug to the right tissue at a useful concentration is harder than it looks. This lesson explains the routes used in ophthalmology, why most of an eye drop never enters the eye, what makes a molecule cross the cornea, and how a drop put in the eye can slow the heart. These principles explain the practical rules taught to every patient who uses drops.

10 minute read5 linked questions

The routes and what each one reaches

A drug can be delivered to the eye from the front, from the side, directly into it, or through the blood. The choice depends on which tissue is the target. Drops and ointments reach the ocular surface and the anterior segment (cornea, anterior chamber, iris and ciliary body) well, but very little of a drop reaches the retina. Disease of the posterior segment (vitreous, retina and choroid) therefore usually needs an injection or a systemic drug.

RouteWhere the drug is placedMain targetTypical example
TopicalConjunctival sac, as drops, gel or ointmentOcular surface and anterior segmentLatanoprost for glaucoma, chloramphenicol for conjunctivitis
SubconjunctivalUnder the conjunctiva, against the scleraAnterior segmentAntibiotic or steroid at the end of surgery
Sub-TenonUnder Tenon's capsule, alongside the globePosterior sclera and the tissues inside itLocal anaesthetic block, depot steroid
IntracameralInto the anterior chamberAnterior segmentCefuroxime at the end of cataract surgery
IntravitrealInto the vitreous cavity through the pars planaRetina and choroidAnti-VEGF drugs, antibiotics for endophthalmitis
SystemicBy mouth or intravenouslyAny tissue the blood barriers allowAcetazolamide, oral aciclovir, oral prednisolone
Routes of drug delivery to the eye

The injected routes work by bypassing barriers. A subconjunctival or sub-Tenon injection puts the drug outside the sclera, which is far more permeable than the cornea, and also provides a depot that leaks slowly back into the tear film. An intracameral or intravitreal injection bypasses every barrier and gives a known dose at the target, at the price of the risks of putting a needle into the eye. The BNF states that intracameral and intravitreal injections should only be used under specialist supervision.

3D atlasDrops must cross the cornea; intravitreal injections enter through the pars plana to reach the retina.

Why most of a drop is wasted

The first obstacle is volume. The conjunctival sac normally holds about 7 to 8 microlitres of tears and can stretch to roughly 30 microlitres for a moment. A commercial dropper delivers a drop of around 40 microlitres. Most of the drop therefore spills onto the cheek or is pumped down the lacrimal drainage system by the next blink. Less than about 10 microlitres stays on the eye after a single blink.

The second obstacle is time. Tears are replaced continuously, at roughly a fifth of their volume each minute, and an irritant drop provokes reflex tearing that dilutes it further. Reviews of ocular drug delivery put the useful window for absorption at about five to seven minutes. The result is that only a few per cent of the dose in a drop gets into the eye. The rest is lost to the skin, the nose and the bloodstream.

Three practical rules follow directly from this. The second and third are stated in the BNF:

  • One drop is enough. A second drop of the same medicine simply washes out the first.
  • Leave at least 5 minutes between two different eye preparations, so the first is absorbed before the second arrives.
  • If drops and ointment are due together, the ointment goes in last, because its greasy base would block a drop from reaching the surface.

The corneal barrier

For a drop to reach the aqueous it has to cross the cornea, and the cornea is a sandwich of layers with opposite properties. The epithelium is several cells thick, its cells are joined by tight junctions, and its membranes are fatty. It lets through lipophilic (fat-soluble) molecules, which dissolve in cell membranes, and resists hydrophilic (water-soluble) ones. The stroma underneath makes up about 90% of the corneal thickness and is mostly water held in collagen. It does the reverse: water-soluble molecules diffuse through it easily and fat-soluble ones are held back. The endothelium is a single leaky layer and is a lesser barrier. The pattern is often summarised as lipid, water, lipid.

3D atlasThe epithelium favours fat-soluble drugs and the stroma favours water-soluble drugs.

A drug that penetrates well therefore needs to be soluble in both fat and water, and small. Several features of drug design and formulation exploit this:

  • Weak bases and weak acids exist as a mixture of uncharged and charged forms. The uncharged form crosses the epithelium and the charged form crosses the stroma. Many eye drugs, including atropine, pilocarpine and the local anaesthetics, are of this type.
  • A prodrug is an inactive, more fat-soluble version that is converted to the active drug in the eye. The corneal epithelium is rich in esterases, so ester prodrugs are split as they cross it. Latanoprost is an ester of this kind.
  • Steroid salts differ: prednisolone acetate is more fat-soluble than prednisolone sodium phosphate, so the acetate penetrates an intact cornea better.
  • A damaged epithelium removes the main barrier. An abrasion or ulcer lets water-soluble drugs such as fluorescein and many antibiotics pass far more easily.

The conjunctiva is a second way in. Its cells are more loosely joined than those of the cornea, so larger and more water-soluble molecules can cross it and then the sclera. The conjunctiva is also full of blood vessels, so much of what is absorbed there is carried away into the circulation instead of into the eye.

Drops, ointments and preservatives

Formulation changes how long the drug stays in contact with the eye. A watery solution is cleared quickly. A suspension, a gel or an ointment stays longer, which raises absorption and allows less frequent dosing. Timolol, for example, is given twice daily as a solution and once daily as a long-acting gel.

DropsOintment
Contact timeMinutesMuch longer
Effect on visionBrief blurSmeared vision, so often used at night
Loss down the nasolacrimal ductCommonMuch less
Contact lensesSoft lenses usually removed firstNever used with lenses
Order if both are dueFirstLast
Drops and ointments compared

Multi-dose bottles contain a preservative to stop bacteria growing after opening. The commonest is benzalkonium chloride (BAK), a detergent. The same detergent action that kills bacteria also disrupts the tight junctions of the corneal epithelium. This slightly improves drug penetration, but with long-term use it damages the ocular surface, causing stinging, punctate epithelial staining and worsening dry eye. The harm grows with the number of preserved drops used each day, which matters for a glaucoma patient on three bottles for life.

The BNF advises preservative-free drops for patients who are allergic to preservatives or who have clinically significant ocular surface disease, and prefers preservative-free lubricants when they are used frequently and long term. Preservatives also build up in soft contact lenses, so lenses are removed before preserved drops go in. Preservative-free products come as single-use vials or in bottles with a filter or valve. An opened multi-dose bottle is normally discarded after 4 weeks.

Systemic absorption from a drop

The part of a drop that drains through the puncta runs down the nasolacrimal duct into the nose. The nasal mucosa is thin and very vascular, so drug is absorbed quickly into the blood. Unlike a tablet, this dose does not pass through the liver first, so nothing is removed by first-pass metabolism. A drop behaves a little like a small intravenous dose. Some drug is also absorbed directly through conjunctival vessels.

This is why topical drugs carry systemic warnings. The BNF tells prescribers to consider all the contraindications of systemic beta blockers before giving timolol drops, which can cause bradycardia and bronchospasm. Cyclopentolate and atropine can cause flushing, dry mouth, tachycardia and confusion, particularly in children and older people. Phenylephrine 10% can raise blood pressure. Babies are at most risk because the drop is the same size but the body is much smaller.

The countermeasure is punctal occlusion: pressing a fingertip over the inner corner of the closed eye, on the lacrimal sac, after the drop goes in. The BNF advises pressure for at least a minute. This reduces drainage to the nose, which lowers systemic absorption and at the same time keeps the drug on the eye for longer.

Reaching the eye through the blood

A drug in the bloodstream meets two barriers. The blood-aqueous barrier is formed by the tight junctions of the non-pigmented ciliary epithelium and of the iris vessels. The blood-retinal barrier has an inner part, the tight junctions between retinal capillary endothelial cells, and an outer part, the tight junctions between cells of the retinal pigment epithelium. Together they keep most drugs out: only a very small fraction of a systemic dose reaches the inside of the eye.

Systemic treatment is still chosen in three situations. The first is when the drug is small and fat-soluble enough to cross, as with acetazolamide. The second is when the target is outside the barriers or the disease is not confined to the eye, as with oral antibiotics for orbital cellulitis or immunosuppression for scleritis. The third is when inflammation has broken the barriers down, which lets more drug in. When none of these applies and the retina is the target, the drug is injected into the vitreous. The individual routes are picked up again in the lessons on intravitreal treatment and on local anaesthesia.

One last pharmacokinetic point is pigment. Many drugs bind to melanin in the iris and ciliary body, which acts as a reservoir. A darkly pigmented iris soaks up more of a dilating drop, so it dilates more slowly and less fully than a blue one. The BNF warns that this resistance should not lead to repeated dosing and overdose.

Summary

  • Drops reach the anterior segment; posterior segment disease usually needs intravitreal or systemic treatment.
  • The conjunctival sac holds about 7 to 8 microlitres and a drop is around 40 microlitres, so most of every drop is lost.
  • Only a few per cent of a topical dose enters the eye, mainly through the cornea.
  • The corneal epithelium favours fat-soluble molecules and the stroma favours water-soluble ones, so the best drugs are soluble in both.
  • Leave at least 5 minutes between different eye preparations and put ointment in last.
  • Benzalkonium chloride is the commonest preservative and damages the ocular surface with long-term use.
  • Drops drain to the nasal mucosa and are absorbed without first-pass metabolism, so timolol drops can cause bradycardia and bronchospasm.
  • Pressing over the punctum for at least a minute reduces systemic absorption and prolongs contact with the eye.
  • The blood-aqueous and blood-retinal barriers keep most systemic drugs out of the eye.

Check yourself

Quick recall on this lesson. These are easier than the question bank.

1. Which layer of the cornea is the main barrier to a water-soluble drug?
2. What is the minimum interval the BNF advises between two different eye drops?
3. Why can timolol eye drops cause bradycardia?
4. Which preservative is most commonly found in multi-dose eye drops?
Practise 5 questions on this lesson

Written for revision. It is not a source of clinical advice, and guidance changes.